CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SPAG9 (ImmuneEditome ID:9043)

1. Gene summary of enriched editing regions for SPAG9

check button Gene summary
Gene informationGene symbol

SPAG9

Gene ID

9043

GeneSynonymsCT89|HLC-6|HLC4|HLC6|JIP-4|JIP4|JLP|PHET|PIG6
GeneCytomap

17q21.33

GeneTypeprotein-coding
GeneDescriptionC-Jun-amino-terminal kinase-interacting protein 4|JNK interacting protein|JNK/SAPK-associated protein|Max-binding protein|c-Jun NH2-terminal kinase-associated leucine zipper protein|cancer/testis antigen 89|human lung cancer oncogene 6 protein|lung cancer oncogene 4|mitogen-activated protein kinase 8-interacting protein 4|proliferation-inducing gene 6|protein highly expressed in testis|sperm surface protein|sunday driver 1
GeneModificationdate20230329
UniprotIDO60271;H0YBE9;H0Y981;D6RHI8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:50964294-50965083:-ENST00000509724.1ENSG00000008294.19SPAG9ncRNA_exonicAluJb,AluSxchr17:50964294-50965083:-.alignment
chr17:50971136-50971655:-ENST00000506500.1ENSG00000008294.19SPAG9ncRNA_intronicAluSc8,(AAAC)n,AluJr4chr17:50971136-50971655:-.alignment
chr17:50991680-50992965:-ENST00000505173.4ENSG00000008294.19SPAG9ncRNA_intronicAluSx1,L1MB1,AluSq2,L1MB4,AluSx4,AluJb,(T)nchr17:50991680-50992965:-.alignment
chr17:50991680-50992965:-ENST00000514613.4ENSG00000008294.19SPAG9ncRNA_intronicAluSx1,L1MB1,AluSq2,L1MB4,AluSx4,AluJb,(T)nchr17:50991680-50992965:-.alignment
chr17:50996925-50998352:-ENST00000505173.4ENSG00000008294.19SPAG9ncRNA_intronicL2a,AluSx4,AluSq2,MIRbchr17:50996925-50998352:-.alignment
chr17:50996925-50998352:-ENST00000513827.4ENSG00000008294.19SPAG9ncRNA_intronicL2a,AluSx4,AluSq2,MIRbchr17:50996925-50998352:-.alignment
chr17:50996925-50998352:-ENST00000514613.4ENSG00000008294.19SPAG9ncRNA_intronicL2a,AluSx4,AluSq2,MIRbchr17:50996925-50998352:-.alignment
chr17:51026756-51027341:-ENST00000505173.4ENSG00000008294.19SPAG9ncRNA_intronicAluSz,AluSpchr17:51026756-51027341:-.alignment
chr17:51026756-51027341:-ENST00000514613.4ENSG00000008294.19SPAG9ncRNA_intronicAluSz,AluSpchr17:51026756-51027341:-.alignment
chr17:51026756-51027341:-ENST00000576492.1ENSG00000008294.19SPAG9ncRNA_intronicAluSz,AluSpchr17:51026756-51027341:-.alignment
chr17:51086016-51086911:-ENST00000262013.10ENSG00000008294.19SPAG9intronicAluSg7,AluSx,AluSx3chr17:51086016-51086911:-.alignment
chr17:51086016-51086911:-ENST00000357122.7ENSG00000008294.19SPAG9intronicAluSg7,AluSx,AluSx3chr17:51086016-51086911:-.alignment
chr17:51086016-51086911:-ENST00000505279.4ENSG00000008294.19SPAG9intronicAluSg7,AluSx,AluSx3chr17:51086016-51086911:-.alignment
chr17:51086016-51086911:-ENST00000618113.3ENSG00000008294.19SPAG9intronicAluSg7,AluSx,AluSx3chr17:51086016-51086911:-.alignment
chr17:51108625-51111784:-ENST00000262013.10ENSG00000008294.19SPAG9intronicAluSc8,AluSp,AluSx1,L1ME2z,AluJo,AluJb,(AATTTA)n,L1MC4,AluSgchr17:51108625-51111784:-.alignment
chr17:51108625-51111784:-ENST00000357122.7ENSG00000008294.19SPAG9intronicAluSc8,AluSp,AluSx1,L1ME2z,AluJo,AluJb,(AATTTA)n,L1MC4,AluSgchr17:51108625-51111784:-.alignment
chr17:51108625-51111784:-ENST00000505279.4ENSG00000008294.19SPAG9intronicAluSc8,AluSp,AluSx1,L1ME2z,AluJo,AluJb,(AATTTA)n,L1MC4,AluSgchr17:51108625-51111784:-.alignment
chr17:51108625-51111784:-ENST00000618113.3ENSG00000008294.19SPAG9intronicAluSc8,AluSp,AluSx1,L1ME2z,AluJo,AluJb,(AATTTA)n,L1MC4,AluSgchr17:51108625-51111784:-.alignment
chr17:51114195-51116341:-ENST00000262013.10ENSG00000008294.19SPAG9intronicAluSx,AluJo,AluSg,AluSz,AluSx1,AluSpchr17:51114195-51116341:-.alignment
chr17:51114195-51116341:-ENST00000357122.7ENSG00000008294.19SPAG9intronicAluSx,AluJo,AluSg,AluSz,AluSx1,AluSpchr17:51114195-51116341:-.alignment
chr17:51114195-51116341:-ENST00000505279.4ENSG00000008294.19SPAG9intronicAluSx,AluJo,AluSg,AluSz,AluSx1,AluSpchr17:51114195-51116341:-.alignment
chr17:51114195-51116341:-ENST00000618113.3ENSG00000008294.19SPAG9intronicAluSx,AluJo,AluSg,AluSz,AluSx1,AluSpchr17:51114195-51116341:-.alignment


Top

2. Tumor-specific enriched editing regions for SPAG9


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:50964294-50965083:-BRCAEER1.6426e-04image
ENSG00000008294.19,SPAG9BRCAEAG1.3679e-04image
chr17:50964294-50965083:-COADEER1.6777e-07image
ENSG00000008294.19,SPAG9COADEAG8.9143e-08image
chr17:50964294-50965083:-HNSCEER1.0615e-02image
ENSG00000008294.19,SPAG9HNSCEAG8.2422e-03image
chr17:50964294-50965083:-LUSCEER7.1248e-07image
ENSG00000008294.19,SPAG9LUSCEAG7.4259e-07image
chr17:50964294-50965083:-THCAEER7.1866e-19image
ENSG00000008294.19,SPAG9THCAEAG8.0652e-20image
chr17:50964294-50965083:-UCECEER1.5289e-02image
ENSG00000008294.19,SPAG9UCECEAG1.7143e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr17:50964294-50965083:-KIRCPathEER1.1105e-031.0207e-040.1722image
ENSG00000008294.19,SPAG9KIRCPathEAG2.8041e-041.9625e-050.1873image
chr17:50964294-50965083:-LUADPathEER1.3112e-025.2363e-030.1320image
ENSG00000008294.19,SPAG9LUADPathEAG3.1664e-021.1186e-020.1194image
chr17:51114195-51116341:-STADPathEER1.1088e-028.1587e-040.4275image
chr17:50964294-50965083:-THCAPathEER1.8918e-022.2510e-020.1057image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr17:51108625-51111784:-ESCAEER5.1869e-036.1978e-032.3290e+03image

Top

3. Enriched editing regions and immune related genes for SPAG9


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:50964294-50965083:-GBMEERENSG00000144233,AMMECR1L-0.48156.9615e-077.1252e-08-0.4056imageNCPSF6NAMonocytesGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:50964294-50965083:-GBMEERENSG00000223722,RP11-467L13.50.46731.7523e-064.5255e-080.4112imageNNNAMacrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:50964294-50965083:-GBMEERENSG00000230191,RP4-725G10.30.44256.8307e-062.6106e-080.4178imageNNNAMacrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:50964294-50965083:-GBMEERENSG00000229230,MT1P30.38071.6951e-049.8928e-080.4015imageNNNAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr17:50964294-50965083:-GBMEERENSG00000230204,FTH1P50.38122.8863e-041.3600e-100.4746imageNNNAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr17:50964294-50965083:-GBMEERENSG00000256745,RP11-680H20.10.37463.8593e-044.8992e-100.4617imageNNNAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:50964294-50965083:-GBMEERENSG00000237264,FTH1P110.36206.7089e-041.2873e-110.4971imageNNNAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr17:50964294-50965083:-GBMEERENSG00000227376,FTH1P160.35539.3475e-042.7630e-100.4675imageNNNAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr17:50964294-50965083:-GBMEERENSG00000223361,FTH1P100.35201.0816e-031.0643e-110.4988imageNNNAMonocytesGSVA_HALLMARK_MITOTIC_SPINDLE
chr17:50964294-50965083:-GBMEERENSG00000242960,FTH1P230.34371.5442e-032.0431e-110.4928imageNNNAMonocytesGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for SPAG9


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000008294.19,SPAG9
ESCAEAGMEXENSG00000158856.13chr822080411:22080460:22080617:22080625:22080794:22080870:22081112:22081193-0.38563.8600e-031.7223e-07-0.4014imageNADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184NAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_DN
chr17:50964294-50965083:-
GBMEERIRENSG00000177963.8chr11213448:213497:214229:214516-0.31961.3550e-038.8154e-07-0.4345imageNCPSF6NANeutrophilsGSVA_HALLMARK_ADIPOGENESIS
ENSG00000008294.19,SPAG9
GBMEAGIRENSG00000119688.16chr1474287809:74287886:74288715:742887650.25535.4491e-032.9158e-060.4074imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184ABCD4T_cells_regulatory_(Tregs)GSVA_HALLMARK_GLYCOLYSIS
chr17:50964294-50965083:-
GBMEERIRENSG00000102978.8chr1657469960:57470129:57470210:57470271-0.28828.8454e-032.5323e-06-0.4128imageNCPSF6NAMonocytesGSVA_HALLMARK_ADIPOGENESIS
ENSG00000008294.19,SPAG9
GBMEAGIRENSG00000179304.12chrX52897295:52897409:52899467:52899541-0.40041.6945e-044.0992e-10-0.4809imageNACIN1;ADAR;AUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;EIF4G2;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LIN28B;LSM11;NONO;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAMacrophages_M0GSVA_HALLMARK_ADIPOGENESIS
ENSG00000008294.19,SPAG9
GBMEAGIRENSG00000148362.6chr9136992417:136992704:136992924:136992974-0.39804.4667e-046.1305e-08-0.4086imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAB_cells_naiveGSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000008294.19,SPAG9
GBMEAGIRENSG00000119431.5chr9113375452:113375567:113376728:113376925-0.34409.9609e-045.5735e-08-0.4593imageNAUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP4B;LIN28;LSM11;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_CD8GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000008294.19,SPAG9
GBMEAGIRENSG00000110888.13chr1230713784:30715144:30716507:30716676-0.31035.4799e-035.9846e-07-0.4213imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDC1;ZC3H7B;ZNF184CAPRIN2T_cells_follicular_helperGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr17:50964294-50965083:-
GBMEERIRENSG00000129534.9chr1445203189:45206170:45210379:45210528-0.33521.3620e-031.2218e-06-0.4151imageNCPSF6NAMacrophages_M2GSVA_HALLMARK_PEROXISOME
chr17:50964294-50965083:-
GBMEERIRENSG00000225828.1chr132361269:32361535:32361729:32361824-0.30184.2849e-032.1255e-06-0.4110imageNCPSF6NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for SPAG9


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:50964294-50965083:-ACCEERMacrophages_M21.2334e-020.4128image
ENSG00000008294.19,SPAG9ACCEAGMacrophages_M21.2334e-020.4128image
chr17:50964294-50965083:-BLCAEERMacrophages_M14.2383e-040.2154image
ENSG00000008294.19,SPAG9BLCAEAGMacrophages_M12.5021e-040.2219image
chr17:50964294-50965083:-BRCAEERNK_cells_activated1.2877e-020.0802image
ENSG00000008294.19,SPAG9BRCAEAGNK_cells_activated2.5365e-020.0720image
chr17:50964294-50965083:-CESCEERB_cells_memory1.7752e-02-0.1623image
ENSG00000008294.19,SPAG9CESCEAGB_cells_memory1.5724e-02-0.1645image
chr17:50964294-50965083:-CHOLEERPlasma_cells2.7638e-020.4493image
ENSG00000008294.19,SPAG9CHOLEAGPlasma_cells2.7638e-020.4493image
chr17:50964294-50965083:-COADEEREosinophils7.9437e-03-0.1781image
ENSG00000008294.19,SPAG9COADEAGNK_cells_activated1.4743e-020.1635image
chr17:50964294-50965083:-ESCAEERT_cells_CD87.0567e-080.4104image
chr17:50971136-50971655:-ESCAEERMacrophages_M22.1105e-020.4061image
chr17:50991680-50992965:-ESCAEERT_cells_gamma_delta3.0738e-030.4564image
chr17:50996925-50998352:-ESCAEERMast_cells_resting1.9962e-02-0.2949image
chr17:51026756-51027341:-ESCAEERT_cells_CD4_memory_resting2.1580e-02-0.4047image
chr17:51086016-51086911:-ESCAEERMonocytes4.4398e-02-0.3828image
chr17:51108625-51111784:-ESCAEEREosinophils7.6574e-030.4560image
chr17:51114195-51116341:-ESCAEERNK_cells_activated2.1088e-020.4126image
ENSG00000008294.19,SPAG9ESCAEAGNK_cells_activated3.7479e-050.3189image
chr17:50964294-50965083:-GBMEERMacrophages_M01.9241e-02-0.1826image
ENSG00000008294.19,SPAG9GBMEAGMacrophages_M01.9888e-02-0.1817image
chr17:50964294-50965083:-HNSCEERT_cells_gamma_delta2.5002e-02-0.1107image
ENSG00000008294.19,SPAG9HNSCEAGB_cells_naive2.1388e-02-0.1131image
chr17:50964294-50965083:-KICHEERMast_cells_resting2.6182e-020.2971image
ENSG00000008294.19,SPAG9KICHEAGMast_cells_resting2.6182e-020.2971image
chr17:50964294-50965083:-KIRCEERT_cells_regulatory_(Tregs)4.1905e-050.2124image
ENSG00000008294.19,SPAG9KIRCEAGT_cells_regulatory_(Tregs)2.6678e-050.2162image
chr17:50964294-50965083:-KIRPEERNeutrophils3.8815e-060.2824image
ENSG00000008294.19,SPAG9KIRPEAGNeutrophils3.0795e-060.2842image
chr17:50964294-50965083:-LAMLEERMacrophages_M13.0159e-02-0.3521image
ENSG00000008294.19,SPAG9LAMLEAGDendritic_cells_activated2.0391e-020.2469image
chr17:50964294-50965083:-LGGEERMacrophages_M02.7271e-05-0.1822image
ENSG00000008294.19,SPAG9LGGEAGMacrophages_M03.4766e-05-0.1796image
chr17:50964294-50965083:-LUADEERT_cells_CD4_memory_activated4.6230e-030.1340image
ENSG00000008294.19,SPAG9LUADEAGT_cells_CD4_memory_activated1.4875e-020.1148image
chr17:50964294-50965083:-LUSCEERMast_cells_resting6.1011e-03-0.1313image
ENSG00000008294.19,SPAG9LUSCEAGMast_cells_resting4.3986e-03-0.1362image
chr17:50964294-50965083:-MESOEERT_cells_CD83.1319e-030.3532image
ENSG00000008294.19,SPAG9MESOEAGT_cells_CD83.1319e-030.3532image
chr17:50964294-50965083:-PAADEERMast_cells_activated5.2663e-03-0.2260image
ENSG00000008294.19,SPAG9PAADEAGMast_cells_activated5.1547e-03-0.2258image
chr17:50964294-50965083:-PCPGEERT_cells_CD4_memory_resting2.1452e-03-0.2471image
ENSG00000008294.19,SPAG9PCPGEAGT_cells_CD4_memory_resting2.1452e-03-0.2471image
chr17:50964294-50965083:-PRADEERT_cells_regulatory_(Tregs)4.4149e-030.1510image
ENSG00000008294.19,SPAG9PRADEAGT_cells_regulatory_(Tregs)7.7330e-040.1764image
chr17:50964294-50965083:-READEERMacrophages_M24.9806e-020.2187image
chr17:50964294-50965083:-SARCEERPlasma_cells2.8416e-020.1464image
ENSG00000008294.19,SPAG9SARCEAGMacrophages_M23.3832e-020.1416image
chr17:50964294-50965083:-SKCMEERT_cells_CD81.8020e-030.1501image
ENSG00000008294.19,SPAG9SKCMEAGT_cells_CD81.8978e-030.1492image
chr17:50964294-50965083:-STADEERNK_cells_activated7.1717e-030.1449image
chr17:50971136-50971655:-STADEERB_cells_memory2.9561e-02-0.2788image
chr17:51086016-51086911:-STADEERT_cells_CD81.8117e-020.3176image
chr17:51108625-51111784:-STADEERT_cells_CD4_memory_activated1.7287e-020.2689image
chr17:51114195-51116341:-STADEERDendritic_cells_resting2.8309e-030.3759image
ENSG00000008294.19,SPAG9STADEAGT_cells_CD4_memory_activated4.8440e-040.1845image
ENSG00000008294.19,SPAG9TGCTEAGNK_cells_activated4.7143e-020.1961image
chr17:50964294-50965083:-THCAEERT_cells_regulatory_(Tregs)1.7102e-040.1731image
ENSG00000008294.19,SPAG9THCAEAGT_cells_regulatory_(Tregs)7.6494e-060.2041image
chr17:50964294-50965083:-THYMEERNeutrophils1.2124e-03-0.4080image
ENSG00000008294.19,SPAG9THYMEAGNeutrophils2.0131e-03-0.3848image


Top

6. Enriched editing regions and immune gene sets for SPAG9


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000008294.19,SPAG9THCAEAG4.1152e-02image1.1476e-040.1764image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr17:50964294-50965083:-HNSCEER2.0529e-020.11443.6629e-02-0.10323.3370e-020.10517.0148e-030.1330image
ENSG00000008294.19,SPAG9LUADEAG8.2936e-030.12431.7768e-020.11171.1823e-020.11861.0457e-030.1540image
chr17:50964294-50965083:-LUADEER4.5414e-030.13431.3978e-020.11649.0390e-030.12366.1078e-040.1618image
ENSG00000008294.19,SPAG9STADEAG5.8652e-060.23821.0256e-020.13631.1608e-030.17203.6012e-030.1543image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:50964294-50965083:-BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER1.2550e-080.3414image
ENSG00000008294.19,SPAG9BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG7.6718e-090.3436image
chr17:50964294-50965083:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0256e-080.1759image
ENSG00000008294.19,SPAG9BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.8423e-070.1625image
ENSG00000008294.19,SPAG9CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.9762e-050.2622image
chr17:50964294-50965083:-CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0850e-040.2621image
ENSG00000008294.19,SPAG9CHOLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.3303e-020.4612image
chr17:50964294-50965083:-CHOLGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.3303e-020.4612image
chr17:50996925-50998352:-ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.5499e-02-0.3062image
chr17:51026756-51027341:-ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEER1.5466e-040.6198image
chr17:51114195-51116341:-ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.5675e-030.5438image
ENSG00000008294.19,SPAG9ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.9974e-030.2257image
chr17:50991680-50992965:-ESCAGSVA_HALLMARK_G2M_CHECKPOINTEER1.9365e-020.3683image
chr17:50964294-50965083:-ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.8328e-020.1863image
ENSG00000008294.19,SPAG9GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG7.2937e-050.3047image
chr17:50964294-50965083:-GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER8.0437e-050.3030image
ENSG00000008294.19,SPAG9HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3751e-050.2119image
chr17:50964294-50965083:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.8329e-070.2400image
ENSG00000008294.19,SPAG9KICHGSVA_HALLMARK_ADIPOGENESISEAG4.9773e-02-0.2635image
chr17:50964294-50965083:-KICHGSVA_HALLMARK_ADIPOGENESISEER4.9773e-02-0.2635image
ENSG00000008294.19,SPAG9KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG5.2310e-070.2570image
chr17:50964294-50965083:-KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.7549e-070.2618image
ENSG00000008294.19,SPAG9KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.6417e-05-0.2443image
chr17:50964294-50965083:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER1.9676e-05-0.2619image
ENSG00000008294.19,SPAG9LAMLGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG4.5273e-020.2140image
chr17:50964294-50965083:-LAMLGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.4546e-020.3438image
chr17:51108625-51111784:-LAMLGSVA_HALLMARK_G2M_CHECKPOINTEER2.2869e-020.3425image
chr17:50964294-50965083:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER2.2197e-09-0.2575image
ENSG00000008294.19,SPAG9LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6854e-08-0.2431image
ENSG00000008294.19,SPAG9LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG6.3141e-030.2012image
chr17:50964294-50965083:-LIHCGSVA_HALLMARK_ADIPOGENESISEER4.9872e-030.2073image
chr17:50964294-50965083:-LUADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.0110e-050.1934image
ENSG00000008294.19,SPAG9LUADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG5.4299e-050.1891image
chr17:50964294-50965083:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.0987e-040.1768image
ENSG00000008294.19,SPAG9LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6246e-040.1740image
chr17:50964294-50965083:-MESOGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.9199e-030.3556image
ENSG00000008294.19,SPAG9MESOGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.9199e-030.3556image
chr17:50964294-50965083:-OVGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER4.9958e-020.1286image
ENSG00000008294.19,SPAG9PAADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.7110e-030.2523image
chr17:50964294-50965083:-PAADGSVA_HALLMARK_GLYCOLYSISEER2.6763e-030.2427image
chr17:50964294-50965083:-PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER7.6137e-050.2087image
ENSG00000008294.19,SPAG9PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.3442e-040.1999image
chr17:50964294-50965083:-READGSVA_HALLMARK_NOTCH_SIGNALINGEER2.0554e-020.2570image
chr17:50964294-50965083:-SARCGSVA_HALLMARK_P53_PATHWAYEER1.1367e-030.2161image
ENSG00000008294.19,SPAG9SARCGSVA_HALLMARK_P53_PATHWAYEAG2.1606e-030.2035image
chr17:50964294-50965083:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3497e-040.1831image
ENSG00000008294.19,SPAG9SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4394e-040.1821image
ENSG00000008294.19,SPAG9STADGSVA_HALLMARK_DNA_REPAIREAG3.6777e-070.2663image
chr17:51086016-51086911:-STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.4509e-030.4004image
chr17:50991680-50992965:-STADGSVA_HALLMARK_HEME_METABOLISMEER2.2827e-030.3665image
chr17:50971136-50971655:-STADGSVA_HALLMARK_GLYCOLYSISEER2.2465e-020.2919image
chr17:51114195-51116341:-STADGSVA_HALLMARK_MITOTIC_SPINDLEEER2.1003e-02-0.2950image
chr17:50964294-50965083:-STADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.1548e-050.2344image
chr17:51108625-51111784:-STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER4.3384e-050.4456image
chr17:50964294-50965083:-TGCTGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.4020e-030.2874image
ENSG00000008294.19,SPAG9TGCTGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.9875e-030.2898image
ENSG00000008294.19,SPAG9THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.8675e-080.2550image
chr17:50964294-50965083:-THCAGSVA_HALLMARK_P53_PATHWAYEER2.6592e-110.3020image
chr17:50964294-50965083:-THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER6.5178e-040.4278image
ENSG00000008294.19,SPAG9THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.5309e-040.4394image
ENSG00000008294.19,SPAG9UCECGSVA_HALLMARK_UV_RESPONSE_UPEAG4.9640e-020.2275image
ENSG00000008294.19,SPAG9UCSGSVA_HALLMARK_MYOGENESISEAG1.8739e-02-0.4132image
chr17:50964294-50965083:-UCSGSVA_HALLMARK_MYOGENESISEER1.8739e-02-0.4132image
chr17:50964294-50965083:-UVMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.1987e-020.2750image
ENSG00000008294.19,SPAG9UVMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.1987e-020.2750image


Top

7. Enriched editing regions and drugs for SPAG9


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000008294.19,SPAG9ACCAZD6244EAG4.2213e-020.3404image
chr17:50964294-50965083:-ACCAZD6244EER4.2213e-020.3404image
chr17:50964294-50965083:-BLCACGP.60474EER1.1840e-07-0.3189image
ENSG00000008294.19,SPAG9BLCACGP.60474EAG3.7446e-08-0.3283image
chr17:50964294-50965083:-BRCADasatinibEER8.0790e-05-0.1270image
ENSG00000008294.19,SPAG9BRCADasatinibEAG1.5334e-04-0.1217image
ENSG00000008294.19,SPAG9CESCAZD.2281EAG1.4251e-03-0.2162image
chr17:50964294-50965083:-CESCAZD.2281EER1.4035e-03-0.2175image
ENSG00000008294.19,SPAG9CHOLMidostaurinEAG2.1891e-03-0.5944image
chr17:50964294-50965083:-CHOLMidostaurinEER2.1891e-03-0.5944image
ENSG00000008294.19,SPAG9COADJNJ.26854165EAG7.0329e-03-0.1804image
chr17:50964294-50965083:-COADDasatinibEER1.7484e-02-0.1597image
chr17:51026756-51027341:-ESCAErlotinibEER1.4289e-02-0.4290image
chr17:51114195-51116341:-ESCACCT007093EER1.4153e-020.4362image
ENSG00000008294.19,SPAG9ESCACGP.60474EAG1.6744e-04-0.2924image
chr17:50991680-50992965:-ESCAGW843682XEER5.4084e-03-0.4317image
chr17:51108625-51111784:-ESCABosutinibEER2.3477e-02-0.3935image
chr17:50964294-50965083:-ESCABortezomibEER1.0173e-05-0.3411image
chr17:50996925-50998352:-ESCACytarabineEER3.3649e-03-0.3668image
chr17:50964294-50965083:-GBMCGP.082996EER1.0132e-06-0.3709image
ENSG00000008294.19,SPAG9GBMCGP.082996EAG8.6121e-07-0.3732image
ENSG00000008294.19,SPAG9HNSCAUY922EAG3.5418e-06-0.2256image
chr17:50964294-50965083:-HNSCAUY922EER2.8491e-05-0.2051image
ENSG00000008294.19,SPAG9KIRCDasatinibEAG3.4070e-11-0.3365image
chr17:50964294-50965083:-KIRCBMS.536924EER3.3472e-11-0.3379image
chr17:50964294-50965083:-KIRPBAY.61.3606EER2.2947e-060.2888image
ENSG00000008294.19,SPAG9KIRPBAY.61.3606EAG3.1700e-060.2838image
ENSG00000008294.19,SPAG9LAMLCEP.701EAG4.7191e-020.2122image
chr17:51108625-51111784:-LAMLLapatinibEER4.9938e-020.2974image
chr17:50964294-50965083:-LAMLAZD.0530EER2.9248e-02-0.3540image
chr17:50964294-50965083:-LGGMG.132EER4.8812e-14-0.3212image
ENSG00000008294.19,SPAG9LGGMG.132EAG2.0783e-12-0.3004image
ENSG00000008294.19,SPAG9LIHCMG.132EAG3.4678e-03-0.2168image
chr17:50964294-50965083:-LIHCMG.132EER3.4678e-03-0.2168image
chr17:50964294-50965083:-LUADBMS.509744EER1.2710e-05-0.2053image
ENSG00000008294.19,SPAG9LUADDocetaxelEAG6.3647e-05-0.1874image
ENSG00000008294.19,SPAG9LUSCAP.24534EAG2.4554e-030.1447image
chr17:50964294-50965083:-LUSCAP.24534EER2.0700e-030.1473image
chr17:50964294-50965083:-MESOCisplatinEER3.3007e-04-0.4226image
ENSG00000008294.19,SPAG9MESOCisplatinEAG3.3007e-04-0.4226image
chr17:50964294-50965083:-OVGDC0941EER1.6680e-02-0.1567image
ENSG00000008294.19,SPAG9OVJW.7.52.1EAG2.2403e-02-0.1489image
ENSG00000008294.19,SPAG9PAADCMKEAG1.4113e-03-0.2567image
chr17:50964294-50965083:-PAADCMKEER3.9603e-03-0.2332image
chr17:50964294-50965083:-PRADBMS.536924EER8.7413e-06-0.2338image
ENSG00000008294.19,SPAG9PRADBMS.536924EAG6.3675e-07-0.2596image
ENSG00000008294.19,SPAG9READMG.132EAG1.5980e-02-0.2638image
chr17:50964294-50965083:-READBIRB.0796EER2.5759e-020.2477image
ENSG00000008294.19,SPAG9SARCBIRB.0796EAG8.4076e-05-0.2591image
chr17:50964294-50965083:-SARCBIRB.0796EER2.5466e-04-0.2421image
chr17:50964294-50965083:-SKCMAZD6244EER2.7361e-04-0.1746image
ENSG00000008294.19,SPAG9SKCMAZD6244EAG3.2727e-04-0.1723image
chr17:50991680-50992965:-STADAZD6244EER3.3740e-02-0.2598image
chr17:51108625-51111784:-STADBexaroteneEER1.4273e-020.2765image
chr17:50964294-50965083:-STADCCT007093EER6.0530e-030.1479image
ENSG00000008294.19,SPAG9STADDocetaxelEAG7.5402e-04-0.1783image
chr17:50971136-50971655:-STADAZD6482EER3.0617e-020.2771image
chr17:51114195-51116341:-STADAMG.706EER4.2874e-02-0.2602image
chr17:51026756-51027341:-STADGefitinibEER1.9089e-02-0.2816image
chr17:51086016-51086911:-STADGemcitabineEER8.1853e-03-0.3531image
chr17:50964294-50965083:-TGCTGW.441756EER9.0113e-03-0.2574image
ENSG00000008294.19,SPAG9TGCTGW.441756EAG9.1445e-03-0.2557image
ENSG00000008294.19,SPAG9THCAAZD6244EAG1.2984e-19-0.4005image
chr17:50964294-50965083:-THCAAZD6244EER9.4081e-20-0.4039image
ENSG00000008294.19,SPAG9THYMABT.888EAG1.9504e-030.3859image
chr17:50964294-50965083:-THYMBryostatin.1EER2.1401e-03-0.3888image
ENSG00000008294.19,SPAG9UCECBI.D1870EAG6.0237e-03-0.3143image
chr17:50964294-50965083:-UCECBI.D1870EER2.7278e-02-0.2639image
chr17:50964294-50965083:-UCSCisplatinEER1.8974e-03-0.5280image
ENSG00000008294.19,SPAG9UCSCisplatinEAG1.8974e-03-0.5280image
chr17:50964294-50965083:-UVMAG.014699EER2.8731e-040.4487image
ENSG00000008294.19,SPAG9UVMAG.014699EAG2.8731e-040.4487image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType